Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.
Stoter
G
G
Rotterdam Cancer Institute, The Netherlands.
Shiloni
E
E
Gundersen
S
S
Cleton
F J
FJ
Iacobelli
S
S
Bijman
J T
JT
Palmer
P
P
Franks
C R
CR
Rodenhuis
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction
D007376:Interleukin-2; D011994:Recombinant Proteins; D003606:Dacarbazine